Shares of Digirad Co. (NASDAQ:DRAD) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 1 year consensus price objective of $6.00 for the company, according to Zacks. Zacks has also assigned Digirad an industry rank of 209 out of 265 based on the ratings given to related companies.

Several equities analysts recently issued reports on the stock. B. Riley reissued a “buy” rating and set a $6.00 price objective on shares of Digirad in a research note on Thursday, October 5th. TheStreet downgraded shares of Digirad from a “c” rating to a “d+” rating in a research note on Friday, November 3rd.

A number of hedge funds have recently modified their holdings of the stock. Punch & Associates Investment Management Inc. increased its position in Digirad by 2.3% during the second quarter. Punch & Associates Investment Management Inc. now owns 1,277,781 shares of the medical equipment provider’s stock worth $5,175,000 after purchasing an additional 28,159 shares during the last quarter. ARS Investment Partners LLC increased its position in Digirad by 3.4% during the second quarter. ARS Investment Partners LLC now owns 667,026 shares of the medical equipment provider’s stock worth $2,701,000 after purchasing an additional 22,233 shares during the last quarter. Kennedy Capital Management Inc. increased its position in Digirad by 37.5% during the second quarter. Kennedy Capital Management Inc. now owns 227,935 shares of the medical equipment provider’s stock worth $923,000 after purchasing an additional 62,120 shares during the last quarter. New York State Common Retirement Fund increased its position in Digirad by 22.0% during the third quarter. New York State Common Retirement Fund now owns 172,901 shares of the medical equipment provider’s stock worth $597,000 after purchasing an additional 31,200 shares during the last quarter. Finally, Macquarie Group Ltd. acquired a new position in Digirad during the third quarter worth approximately $367,000. 53.08% of the stock is owned by hedge funds and other institutional investors.

Digirad (NASDAQ:DRAD) opened at $2.37 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.07 and a current ratio of 1.44. The stock has a market cap of $48.13, a P/E ratio of 8.28 and a beta of 1.89. Digirad has a one year low of $1.90 and a one year high of $5.68.

Digirad (NASDAQ:DRAD) last announced its quarterly earnings data on Friday, November 3rd. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.04. The business had revenue of $28.56 million for the quarter, compared to the consensus estimate of $31.21 million. Digirad had a negative net margin of 9.93% and a positive return on equity of 9.82%. research analysts forecast that Digirad will post 0.09 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, November 30th. Investors of record on Monday, November 20th were given a dividend of $0.055 per share. This represents a $0.22 annualized dividend and a yield of 9.28%. The ex-dividend date of this dividend was Friday, November 17th. Digirad’s dividend payout ratio (DPR) is -37.93%.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Set $6.00 Price Target for Digirad Co. (DRAD)” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/12/08/zacks-brokerages-set-6-00-price-target-for-digirad-co-drad.html.

Digirad Company Profile

Digirad Corporation provides healthcare solutions. The Company’s segments include Diagnostic Services, Mobile Healthcare, Diagnostic Imaging and Medical Device Sales and Services. Through Diagnostic Services, the Company offers an imaging services program as an alternative to purchasing equipment or outsourcing the procedures to another physician or imaging center.

Get a free copy of the Zacks research report on Digirad (DRAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Digirad Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad Co. and related companies with MarketBeat.com's FREE daily email newsletter.